Chapter 12 New trouble - tight funds!
The next morning, Zhang Yang arrived at the clinical trial center early.
Now his daily job is very simple. In addition to recruiting as many subjects as possible, he also maintains communication with the clinical center and solves problems encountered in clinical trials in a timely manner.
After staying in the clinical trial center until ten in the morning, he came to the hematology inpatient department.
In fact, in the division of labor in clinical trials of innovative drugs, clinical trial centers are responsible for more work such as patient enrollment, examination, and drug administration after recruitment.
The bulk of the work of recruiting subjects actually falls on the major departments.
The reason is also very simple. Department doctors know the patient's condition better and are more likely to recommend patients to participate in clinical trials of innovative drugs.
So generally speaking, after major pharmaceutical companies start clinical recruitment, they will arrange one or two interns in the inpatient and outpatient departments of the corresponding departments to help contact patients and fill in information.
Zhang Yang is no exception.
The contact person of Qingshan Pharmaceutical in the hematology department is an intern named Li Xue.
"Li Xue, you are busy. How has the recruitment situation been in the past few days?"
Arriving at the hematologist's office, Li Xue was busy sorting out medical records.
Although she is the liaison officer of "Avatrombopag Qingshan", her main job is still an internship in the department.
Seeing Zhang Yang arriving, she hurriedly greeted him warmly.
"Mr. Zhang, you are here, please take a seat."
"The recruitment situation in the past few days has been much better than before. Especially the first batch of patients who participated in the trial in the past few days have reported that the treatment effect is good, and their platelets have increased a lot. Now they are actively promoting it to us."
"Two patients took the initiative to inquire this morning. I estimate that the recruitment work will become smoother and smoother in the future."
Zhang Yang was slightly relieved. This conclusion was similar to what he had imagined.
With the excellent therapeutic effect of "Avatrombopag Qingshan", once word spreads, the subsequent recruitment work should be much easier.
“That’s great, thank you for your hard work!”
"It's not hard, you should do it."
The conversation between the two was simple and direct. After chatting for a few more words, Zhang Yang left the inpatient department.
In the next few days, as Li Xue said, with the personal promotion of the first batch of subjects, many patients who originally waited and watched chose to try it.
Soon,
the recruitment of patients in the second, third and fourth groups was completed, and the second phase clinical trial of "Qingshan Avatrombopag Tablets" began.
Gradually, while "Avatrombopag" continued to recruit new patients, the first batch of fifteen subjects also unknowingly completed the eight-week Phase II clinical trial.
When the two-month complete data was placed in front of Feng Gang, deputy director of the clinical center, he was completely amazed!
The first batch of fifteen patients was divided into the experimental group and the control group (placebo group). In just two months, the clinical data of the eight patients in the experimental group completely overwhelmed the control group!
Moreover, judging from the clinical data of the trial group, the therapeutic effect of "Qingshan Avatropopag" is indeed no different from that of foreign "Avatropopag" which costs up to 7,800 yuan per box!
Feng Gang was shocked, Zhang Yang and Ren Xiaomin were equally happy, but the happiest ones were the first batch of patients who participated in the clinical trial.
They are all patients with blood diseases, and most of them just participated in the trial with a lucky mentality. However, they did not expect that "Avatrombopag" would actually give them such a big surprise just two months later!
Yan Xiaoduo is one of them.
Two years ago, at the age of 30, she was diagnosed with aplastic anemia.
In the past two years, she tried the most effective treatment options such as bone marrow transplantation and ATG, but the final results of both bone marrow transplantation and ATG were not satisfactory.
There was no way, under the doctor's advice, she could only take the most conservative treatment method - drug treatment.
But God seemed to be joking with her. Traditional domestic hormone drugs and blood-raising drugs did not respond well to her. She had no choice but to switch to "Eltrombopag".
Eltrombopag had some effect, and soon her platelets and red blood cells began to rise steadily, from 10 to 30 units in one month.
But the price of more than 2,000 yuan per box really made her feel distressed, and a checkup showed that the transaminase and bilirubin in the liver increased rapidly.
The final diagnosis was - acute liver injury.
She knew very well that this was the side effect of "Eltrombopag".
But between maintaining life and liver toxicity, does she have a choice?
The doctor had no choice but to recommend her to take a better drug. To this day, she still remembers the doctor’s exact words. "This is the best thrombopoietin in the world. You can try this medicine, but it is a bit expensive."
"How much more expensive can it be?"
But when she checked online, she suddenly became desperate.
This imported drug called "Avatrombopag" costs up to 7,800 yuan per box, totaling 400 yuan per pill.
This kind of medicine is not affordable for ordinary people like her!
Yan Xiaoduo was desperate, so she had no choice but to take Eltrombopag, which had severe side effects, and liver-protecting proprietary Chinese medicines.
This is life!
Until one day, she accidentally saw an advertisement for a Phase II clinical innovative drug...
"Aoyama Avaqupopa"!
Thinking of this, Yan Xiaoduo came back to his senses and couldn't help but take a look at the test results he just got in his hand.
The three most important indicators for blood patients:
[Platelets...80, normal! 】
【Red blood cells...3, normal! 】
[White blood cells...2.8, normal! 】
Although the platelets are still at the lower limit of the normal value, compared with the platelets that often only have more than 10, 20 or even single digits in recent years, this is already the best blood picture in recent years. !
She has already asked the doctor that as long as she can maintain this blood condition, there will be no problem in living a normal and stable life!
It may even be possible to return to normal!
Yan Xiaoduo was completely excited. He could no longer suppress his excitement and excitement. He hurriedly opened the patient group on his mobile phone, then took a picture of the report sheet in his hand and sent it to the group. She couldn't wait to share her joy with other patients.
"@everyone, let’s take a look at the final blood report of the two-month clinical trial!"
It was noon, and just a moment after the message was sent, many people in the group immediately responded.
"Group leader, you finally showed up, let me see your report..."
"His! Xiaoduo, is this really your blood report? Are the platelets normal?"
"Holy shit, is it true? Xiaoduo, the new drug trial you participated in really has such a good clinical effect? I have been taking Eltrombopag for more than half a year and now my platelets are only 60!"< br>
"Oh my god! It's completely beyond my knowledge. To be honest, if you hadn't tried the medicine yourself, I would have thought you were a liar! Is this medicine from Qingshan Pharmaceutical really so effective? Or, "Avatrombopag" "Is the effect really so good?"
"I was also shocked. It has only been two months since my platelets returned to normal. Have any of you in the group taken this?" "Avatrombopag"? Can you tell me how effective "Avatrombopag" is? "
"No one in our group can afford this medicine, even the doctors in our hospital. I have never seen this medicine before!”
Yan Xiaoduo could fully understand the shock of the patients, and she began to patiently answer every question in the group.
Obviously, as one of the first people to undergo two months of "Avatrombopag" treatment, she is qualified to answer questions!
However, just when the patients were excited, Zhang Yang found that as more and more patients enrolled, his funds began to fail to keep up.
Clinical trials, as the name suggests, are tests applied to living humans.
But everyone knows that the emergence of a new drug is always accompanied by a lot of uncertainty, such as whether it has liver toxicity, whether it has nephrotoxicity, and whether it will affect human organs?
So, if a new drug wants to recruit enough patients, it not only needs the drug to be symptomatic, but also needs to compensate the patients during recruitment.
The number can range from tens of thousands to hundreds.
"Avatrombopag Qingshan" naturally also provided each subject with a substantial fee.
As a last resort,
Faced with the funding gap at this time, Zhang Yang could only choose to mortgage his house and car. No matter what, he had to carry out the second phase of clinical trials!
At this time,
the discussion about "Qingshan Avatropol Tablets" among the patients became more and more heated, and successfully attracted the attention of other pharmaceutical companies. Industry, information about Zhang Yang and Ren Xiaomin were put on the desk.
(End of this chapter)